Marijuana is addictive, especially with the high potency products. And with addiction come withdrawal. Withdrawal of THC is not like withdrawal from fentanyl or alcohol. It is more like withdrawal from nicotine - insomnia, anxiety, headaches. The symptoms last about 2 weeks and there are no medications to help. However, going up the FDA rapid approval pathway is a new medication. We talk about this treatment in this podcast.
Ginger Constantine, M.D. is the Chairperson, Co-Founder & CEO of PleoPharma.
Ginger Constantine, MD – Chairperson and CEO - with over 25 years of pharmaceutical regulatory and clinical development experience with the approval of more than 15 products filing numerous INDs, NDAs, and MAAs. Previous Vice President of Women's Health & Bone Repair Clinical Research at Wyeth Pharmaceuticals through its acquisition by Pfizer in 2010. Expertise in Phase 1 through 4 clinical development strategy and execution.
Founded EndoRheum Consultants in 2010, a successful clinical development consulting firm. Member of multiple scientific advisory boards. Has planned, authored and presented numerous scientific studies.
PheoPharma was granted fast-track designation for PP-01, a new investigational drug for cannabis withdrawal syndrome.
A medical marijuana card does not follow the standard of care for prescribing antibiotics or pain medications. There is no benefit-harm calculation for cannabis...
Patty McCarthy, M.S., is the Chief Executive Officer of Faces & Voices of Recovery, a national recovery advocacy organization based in Washington, D.C. Prior...
Canada is number one in marijuana consumption and is also producing large population based public heath research on pot. Dr. Daniel Myran is a...